Imaging lung tumors with peptide-based radioligands

Clinical Lung Cancer

Volumn 5, Issue 2, 2003, Pages 119-124

  Gotthardt, Martin ^a   Béhé, Martin P ^a   Alfke, Heiko ^a   Behr, Thomas M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Lung cancer; Neuroendocrine tumor; Peptide scintigraphy; Somatostatin receptor scintigraphy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN; BOMBESIN; CHOLECYSTOKININ B RECEPTOR; DEPREOTIDE TC 99M; GASTRIN DERIVATIVE; GASTRIN RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GONADORELIN RECEPTOR; INDIUM 111; LAXATIVE; LUTETIUM; NEUROTENSIN RECEPTOR; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RADIOACTIVE IODINE; RADIOLIGAND; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUBSTANCE P RECEPTOR; TECHNETIUM 99M; VASOACTIVE INTESTINAL POLYPEPTIDE; YTTRIUM 90;

ARTICLE; BRONCHUS CARCINOID; CANCER DIAGNOSIS; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; INFLAMMATORY DISEASE; INTESTINE TUMOR; LUNG METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; LUNG SMALL CELL CANCER; LUNG TUMOR; NEUROENDOCRINE TUMOR; RELIABILITY; STANDARD;

EID: 0242351843     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2003.n.026     Document Type: Article

References (44)

1. Lamberts SW, Bakker WH, Reubi JC, et al. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323:1246-1249.
2. Bakker WH, Krenning EP, Reubi JC, et al. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49:1593-1601.
3. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731.
4. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997; 41:63-70.
5. Behr TM, Gotthardt M, Barth A, et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45:189-200.
6. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33:652-658.
7. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-1429.
8. Kwekkeboom DJ, Krenning EF. Somatostatin receptor imaging. Semin Nucl Med 2002; 32:84-91.
9. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112:583-590.
10. Virgolini I, Kurtaran A, Raderer M, et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36:1732-1739.
11. Behr TM, Gotthardt M, Becker W, et al. Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Gottingen/Marburg experience. Nuklearmedizin 2002; 41:71-79.
12. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30:781-793.
13. Reubi JC, Eisenwiener KP, Rink H, et al. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002; 46:45-49.
14. Jamar E Fiasse R, Leners N, et al. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995; 36:542-549.
15. Decristoforo C, Mather SJ, Cholewinski W, et al. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000; 27:1318-1325.
16. Sreedharan SP, Kodama KT, Peterson KE, et al. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989; 264:949-952.
17. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 1999; 115:224-232.
18. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40:539-553.
19. Reubi JC, Lang W, Maurer R, et al. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987; 47:5758-5764.
20. Reubi JC, Waser B, Foekens JA, et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990; 46:416-420.
21. Reubi JC, Waser B, Sheppard M, et al. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 1990; 45:269-274.
22. Reubi JC, Horisberger U, Waser B, et al. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992; 103:1207-1214.
23. Reubi JC, Waser B, van Hagen M, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992; 50:895-900.
24. Ricke J, Klose KJ, Mignon M, et al. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001; 37:8-17.
25. Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumours. Digestion 2000; 62(suppl 1):39-44.
26. Kwekkeboom DJ, Kho GS, Lamberts SW, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21:1106-1113.
27. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. In: Freeman LM, ed. Nuclear Medicine Annual. New York: Raven Press, 1995:1-50.
28. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998; 39:224-227.
29. Goldsmith SJ, Kostakoglu L. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin Ultrasound CT MR 2000; 21:129-138.
30. Fujita T, Yamaji Y, Sato M, et al. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 1994; 55:1797-1806.
31. Reubi JC, Schaer JC, Laissue JA, et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996; 45:39-41.
32. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med 2002; 32:92-96.
33. Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000; 117:1232-1238.
34. Grewal RK, Dadparvar S, Yu JQ, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002; 8:400-404.
35. Gambhir SS, Shepard JE, Handmaker H, et al. Analysis of the cost-effectiveness of a somatostatin analog-99m Tc-depreotide (Neotect) in the scintigraphic evaluation of solitary pulmonary nodules (SPN). J Nucl Med 1999; 40(suppl):57P.
36. Tcherniantchouk O, Waxman AD, Williams CM, et al. Evaluation of hila and mediastinal lymph nodes with Tc-99m depreotide in lung cancer: detection of micrometastases. J Nucl Med 2003; 44(suppl):135P.
37. Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32:148-155.
38. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.
39. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999; 40:1029-1044.
40. Gotthardt M, Schipper ML, Behe M, et al. 111In-DTPA-D-Glu1-minigastrin used for diagnosis of medullary thyroid carcinoma in comparison to 18F-FDG-PET and CT scanning. J Nucl Med 2002; 43(suppl):129P.
41. Reubi JC, Schaer JC, Waser B, et al. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57:1377-1386.
42. Gotthardt M, Grass J, Behe MP, et al. 111In-DTPA-D-Glu1-minigastrin in the diagnosis of gastroinstestinal neuroendocrine tumors: a comparison to 111In-Pentetreotide. J Nucl Med 2003; 44(suppl):74P.
43. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 2002; 29:597-606.
44. Grewal RK, Dadparvar S, Yu JQ, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002; 8:400-404.